ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,314,500 | -65.2% | 24,717 | -66.8% | 0.00% | -50.0% |
| Q2 2023 | $6,641,539 | +332.2% | 74,415 | +419.2% | 0.00% | +100.0% |
| Q1 2023 | $1,536,784 | -76.2% | 14,333 | -72.9% | 0.00% | -66.7% |
| Q4 2022 | $6,459,822 | -12.2% | 52,893 | -25.8% | 0.00% | 0.0% |
| Q3 2022 | $7,361,000 | +95.3% | 71,285 | +75.8% | 0.00% | +50.0% |
| Q2 2022 | $3,770,000 | -79.3% | 40,554 | -73.9% | 0.00% | -66.7% |
| Q1 2022 | $18,224,000 | +260.1% | 155,282 | +312.8% | 0.01% | +200.0% |
| Q4 2021 | $5,061,000 | -44.2% | 37,621 | -33.9% | 0.00% | -33.3% |
| Q3 2021 | $9,067,000 | +414.6% | 56,885 | +324.5% | 0.00% | – |
| Q2 2021 | $1,762,000 | +9.2% | 13,400 | +7.0% | 0.00% | – |
| Q1 2021 | $1,614,000 | -79.0% | 12,521 | -72.8% | 0.00% | -100.0% |
| Q4 2020 | $7,680,000 | +11.0% | 46,054 | +2.7% | 0.00% | 0.0% |
| Q3 2020 | $6,917,000 | -11.7% | 44,823 | -15.4% | 0.00% | -33.3% |
| Q2 2020 | $7,837,000 | +1155.9% | 52,993 | +877.7% | 0.01% | +500.0% |
| Q2 2019 | $624,000 | +149.6% | 5,420 | +42.0% | 0.00% | 0.0% |
| Q1 2018 | $250,000 | -29.0% | 3,817 | -60.7% | 0.00% | 0.0% |
| Q3 2017 | $352,000 | – | 9,704 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |